Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Tachibana, Takayoshi  [Clear All Filters]
2024
Tachibana T, Miyazaki T, Matsumura A, Hagihara M, Tanaka M, Koyama S, Ogusa E, Aoki J, Nakajima Y, Takahashi H, et al. Investigation of biomarkers to predict outcomes in allogeneic hematopoietic stem cell transplantation. Cytotherapy. 2024.
Miyazaki T, Tachibana T, Suzuki T, Izumi A, Fujimaki K, Sato S, Tamai Y, Michishita Y, Suzuki T, Ishii R, et al. Pretransplant inflammatory and nutritional status in elderly allogeneic hematopoietic stem cell transplantation: prognostic value of C-reactive protein-to-albumin ratio. Transplant Cell Ther. 2024.
2023
Ishida H, Shimada H, Tanizawa A, Shimazu Y, Tachibana T, Doki N, Ara T, Matsuo Y, Nara M, Toubai T, et al. Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase chronic myeloid leukemia in the tyrosine kinase inhibitor era. Am J Hematol. 2023.
Nukui J, Tachibana T, Miyazaki T, Tanaka M, Matsumoto K, Ishii Y, Numata A, Nakajima Y, Matsumura A, Suzuki T, et al. Clinical significance of total nucleated cell count in bone marrow of patients with acute lymphoblastic leukemia who underwent allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2023.
Shimomura Y, Komukai S, Kitamura T, Tachibana T, Kurosawa S, Itonaga H, Tsukamoto S, Doki N, Katayama Y, Ito A, et al. The prognosis and risk factors for patients with complex karyotype myelodysplastic syndrome undergoing allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2023.
2021
Harada I, Sasaki H, Murakami K, Nishiyama A, Nakabayashi J, Ichino M, Miyazaki T, Kumagai K, Matsumoto K, Hagihara M, et al. Compromised anti-tumor-immune features of myeloid cell components in chronic myeloid leukemia patients. Sci Rep. 2021;11(1):18046.
2020
Kurosawa S, Shimomura Y, Tachibana T, Ishiyama K, Ota S, Kobayashi T, Uchida N, Fukushima K, Ashida T, Matsuoka K-I, et al. Outcome of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic/myeloproliferative neoplasms-unclassifiable: a retrospective nationwide study of the Japan Society for Hematopoietic Cell Transplantation: Allo-HSCT for patient. Biol Blood Marrow Transplant. 2020.
2019
Kako S, Kanda Y, Onizuka M, Aotsuka N, Usuki K, Tachibana T, Kobayashi T, Kato J, Yano S, Shimizu H, et al. Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: a KSGCT prospective study. Am J Hematol. 2019.
Ando T, Suzuki T, Ishiyama Y, Koyama S, Tachibana T, Tanaka M, Kanamori H, Nakajima H. Impact of Cytomegalovirus Reactivation and Natural Killer Reconstitution on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Single Center Analysis. Biol Blood Marrow Transplant. 2019.
Ohwada C, Sakaida E, Igarashi A, Kobayashi T, Doki N, Mori T, Kato J, Koda Y, Kanamori H, Tanaka M, et al. A Prospective, Longitudinal Observation of the Incidence, Treatment, and Survival of Late Acute and Chronic Graft-versus-host disease by National Institutes of Health Criteria in a Japanese cohort. Biol Blood Marrow Transplant. 2019.